Skip to main content
Scholars@Duke
Menu
About
Schools / Institutes
Browse
construction
release_alert
The Scholars Team is working with OIT to resolve some issues with the Scholars search index
cancel
Mehri Sadri McKellar
Professor of Medicine
Medicine, Infectious Diseases
mehri.mckellar@duke.edu
Duke Box 102359, Durham, NC 27710
Rm 175, Hanes House, Box 102359, Durham, NC 27710
Research
More About This Person
glance {hide_children: true, active: false, enabled: true}
At a Glance
credentials {hide_children: true, active: false, enabled: true}
Credentials
Education
Training & Certifications
academic-experience {hide_children: true, active: false, enabled: true}
Academic Experience
Current Appointments & Affiliations
Previous Appointments & Affiliations
expertise {hide_children: true, active: false, enabled: true}
Expertise
Global Scholarship
research {hide_children: false, active: true, enabled: true}
Research
Selected Grants
publications {hide_children: true, active: false, enabled: true}
Publications
Selected Publications
artistic-works {hide_children: true, active: false, enabled: false}
Artistic Works / Events
teaching {hide_children: true, active: false, enabled: false}
Teaching
advising-mentoring {hide_children: true, active: false, enabled: false}
Advising & Mentoring
recognition {hide_children: true, active: false, enabled: true}
Recognition
In the News
professional-activities {hide_children: true, active: false, enabled: true}
Professional Activities
Outreach & Engaged Scholarship
Manage Profile
Embed Profile Data
Manage Profile
Embed Profile Data
Selected Grants
A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care
Clinical Trial
Principal Investigator ·
Awarded by Gilead Sciences, Inc. ·
2024 - 2030
ISLEND-1 A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir (B/F/TAF)
Clinical Trial
Principal Investigator ·
Awarded by Gilead Sciences, Inc. ·
2024 - 2030
Regional AIDS Education and Training Centers
Inst. Training Prgm or CME
Principal Investigator ·
Awarded by Vanderbilt University Medical Center ·
2015 - 2029
A Phase 2 Randomized, Open-label Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With the Capsid Inhibitor Lenacapavir as Long-Acting Treatment Dosed Every 6 Months in Virologica
Clinical Trial
Principal Investigator ·
Awarded by Gilead Sciences, Inc. ·
2023 - 2027
Ryan White HIV/AIDS Program Part D Coordinated HIV Services and Access to Research for Women, Infants, Children, and Youth (WICY)
Public Service
Physician ·
Awarded by Health Resources and Service Administration ·
2010 - 2026
Integrated Targeted Testing Services (ITTS)
Public Service
Principal Investigator ·
Awarded by NC DHHS ·
2016 - 2026
Ryan White HIV Adult ID Services-Part B
Public Service
Principal Investigator ·
Awarded by Wake County Human Services ·
2022 - 2026
RFA # A-379 Program Area Three Housing Opportunities for Persons with AIDS- Region Six
Public Service
Principal Investigator ·
Awarded by NC Dept of Health and Human Services ·
2016 - 2025
RFA# A-379- Housing Opportunities for Persons with AIDS- Region Seven
Public Service
Principal Investigator ·
Awarded by NC Department of Health and Human Services ·
2015 - 2025
NOTRE: optimizing long-acting pre-exposure prophylaxis and medications for opioid use disorder interventions in carceral settings
Research
Co Investigator ·
Awarded by National Institutes of Health ·
2024 - 2025
Interdisciplinary Research Training Program in AIDS
Inst. Training Prgm or CME
Mentor ·
Awarded by National Institutes of Health ·
2010 - 2025
Ryan White HIV/AIDS Program Part D Support Services
Public Service
Principal Investigator ·
Awarded by New Hanover Regional Medical Center ·
2015 - 2025
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1- The CM Study
Clinical Trial
Principal Investigator ·
Awarded by University of North Carolina - Chapel Hill ·
2023 - 2025
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1- The CM Study
Research
Principal Investigator ·
Awarded by University of North Carolina - Chapel Hill ·
2022 - 2025
MACS/WIHS Combined Cohort Study (MWCCS Clinic Screener)
Research
Principal Investigator ·
Awarded by University of North Carolina - Chapel Hill ·
2023 - 2025
NCDHHS RFA # A-379 -Region 7 Ryan White Part B Network of Care
Public Service
Principal Investigator ·
Awarded by NC Dept of Health and Human Services ·
2016 - 2025
IGHID 11417 - PHI 05 - The Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine Initiated During Acute HIV Infection: Impact on the Latent HIV Reservoir and Long-Term Immunologic Effect
Clinical Trial
Principal Investigator ·
Awarded by University of North Carolina - Chapel Hill ·
2015 - 2024
MATEC Text Messaging Intervention to Improve Antiretroviral Adherence among HIV-Positive Youth (TXTXT)
Inst. Training Prgm or CME
Principal Investigator ·
Awarded by University of Illinois at Chicago ·
2023 - 2024
Effects of I'm Fully Empowered4PrEP Intervention on HIV Prep Uptake by Southern African American Women
Clinical Trial
Principal Investigator ·
Awarded by University of North Carolina - Chapel Hill ·
2022 - 2024
A Multi-level, Salon-Based Intervention to Promote Awareness, Accurate Knowledge and Uptake of PrEP Among Black Women Living in the United States South
Research
Co Investigator ·
Awarded by Gilead Sciences, Inc. ·
2020 - 2024
Ph 2a multicenter, randomized, open label, two part adaptive design study to evaluate the antiviral effect safety and tolerability of GSK 3810109A, an HIV-1 specific broadly neutralizing human monoclonal antibody in antiretroviral naive HIV-1 adults
Clinical Trial
Principal Investigator ·
Awarded by ViiV Healthcare ·
2021 - 2023
The development and validation of a scale to measure Treatment Regimen Fatigue among older adults living with HIV
Research
Co Investigator ·
Awarded by National Institutes of Health ·
2022 - 2023
Modeling the effects of chronic marijuana use on neuroinflammation and HIV-related neuronal injury
Research
Co Investigator ·
Awarded by National Institutes of Health ·
2020 - 2023
Phase IIIb study evaluating switching to long acting Cabo+long acting Rilp Q2months in HIV adults who are virally suppressed
Clinical Trial
Principal Investigator ·
Awarded by ViiV Healthcare ·
2021 - 2023
STYLE 2.0
Public Service
Advisor ·
Awarded by Health Resources and Service Administration ·
2018 - 2023
GS - US - 380-5310
Clinical Trial
Principal Investigator ·
Awarded by Gilead Sciences, Inc. ·
2019 - 2022
Ryan White HIV Adult ID Services, Year 4
Public Service
Principal Investigator ·
Awarded by Wake County Human Services ·
2018 - 2022
A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clnical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1
Clinical Trial
Principal Investigator ·
Awarded by ViiV Healthcare ·
2015 - 2021
Randomized study to evaluate Tocilizumab in patients with severe COVID-19 pneumonia (WA42380)
Clinical Trial
Principal Investigator ·
Awarded by Genentech, Inc. ·
2020 - 2021
BIKTARVY- GS-US-380-4580
Clinical Trial
Principal Investigator ·
Awarded by Gilead Sciences, Inc. ·
2018 - 2020
Bringing PrEP to Campus: Examining Strategies for PrEP Delivery to Historically Black College and Universities (HBCU)
Research
Co Investigator ·
Awarded by National Institutes of Health ·
2005 - 2020
"A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Subjects on Chronic Hemodialysis [GS-US-292-1825]
Clinical Trial
Principal Investigator ·
Awarded by Gilead Sciences, Inc. ·
2016 - 2020
GS-US-380-4030
Clinical Trial
Principal Investigator ·
Awarded by Gilead Sciences, Inc. ·
2017 - 2019
Integrated Targeted Testing Services (ITTS)
Public Service
Principal Investigator ·
Awarded by Durham County Health Department ·
2018 - 2019
Substance Abuse Center (SAC)
Public Service
Principal Investigator ·
Awarded by Wake County Human Services ·
2016 - 2019
Gilead - GS-380-1878
Clinical Trial
Principal Investigator ·
Awarded by Gilead Sciences, Inc. ·
2016 - 2019
GS-US-380-1961
Clinical Trial
Principal Investigator ·
Awarded by Gilead Sciences, Inc. ·
2016 - 2019
HIV Early Intervention Testing
Public Service
Principal Investigator ·
Awarded by Alliance Behavioral Healthcare ·
2016 - 2018
GS-US-380-1489
Clinical Trial
Principal Investigator ·
Awarded by Gilead Sciences, Inc. ·
2016 - 2018
Gilead - GS - US - 380-1844
Clinical Trial
Principal Investigator ·
Awarded by Gilead Sciences, Inc. ·
2016 - 2017
Phase 3 Open-Label Stdy to Eval Switch Opt Stable Antiretro Reg Cont Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
Clinical Trial
Principal Investigator ·
Awarded by Gilead Sciences, Inc. ·
2013 - 2017
GS-US-380-1490
Clinical Trial
Principal Investigator ·
Awarded by Gilead Sciences, Inc. ·
2016 - 2017
Phase 3, 2-part Study to Eval Efficacy of Tenofovir Alafenamide vs Placebo Added to Failing Regimen Followed by Treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Positive Antiretroviral Treatment-Experienced Adults
Clinical Trial
Principal Investigator ·
Awarded by Gilead Sciences, Inc. ·
2013 - 2016
HIV and Asthma in the Post- ART Era
Research
Co Investigator ·
Awarded by National Institutes of Health ·
2014 - 2016
Ryan White Region 6 Network of Care
Public Service
Principal Investigator ·
Awarded by Wake County Human Services ·
2015 - 2016
Substance Abuse Center-5 (SAC-5): Counseling, Testing and Referral in Durham, Caswell, Orange, Person and Wake
Public Service
Principal Investigator ·
Awarded by NC DHHS ·
2015 - 2016
The Youth Education and Prevention (Y.E.P.) Network (Ready-To-Respond Initiative)
Public Service
Principal Investigator ·
Awarded by Department of Health and Human Services ·
2010 - 2016
Bundled Testing and Patient navigation
Public Service
Principal Investigator ·
Awarded by Cape Fear Memorial Foundation ·
2014 - 2015
HIV Early Intervention Testing
Public Service
Principal Investigator ·
Awarded by Alliance Behavioral Healthcare ·
2014 - 2015
Substance Abuse Center-5 (SAC-5): Counseling, Testing and Referral in Durham, Caswell, Orange, Person and Wake
Public Service
Principal Investigator ·
Awarded by NC DHHS ·
2014 - 2015
Housing Opportunities for Persons with AIDS
Public Service
Principal Investigator ·
Awarded by NC Department of Health and Human Services ·
2014 - 2015
Housing Opportunities for Persons with AIDS
Public Service
Principal Investigator ·
Awarded by NC Dept of Health and Human Services ·
2014 - 2015
Ryan White Part B Region 7 Network of Care
Public Service
Principal Investigator ·
Awarded by NC Department of Health and Human Services ·
2014 - 2015
Healthy Relationships: Region Seven Prevention for Positives
Public Service
Principal Investigator ·
Awarded by NC DHHS ·
2014 - 2014
Substance Abuse Center-5 (SAC-5): Counseling, Testing and Referral in Durham, Caswell, Orange, Person and Wake
Public Service
Principal Investigator ·
Awarded by NC DHHS ·
2013 - 2014
FirstSigns-Integration of Prevention in Primary Care Through Training, Testing, and Education
Public Service
Medical Director ·
Awarded by Substance Abuse and Mental Health Services Administration ·
2005 - 2011
